Tanvex BioPharma, Inc. (TPE:6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
53.70
-0.50 (-0.92%)
May 29, 2025, 1:30 PM CST

Tanvex BioPharma Balance Sheet

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Cash & Equivalents
1,077376.96380.75786.232,2232,069
Upgrade
Cash & Short-Term Investments
1,077376.96380.75786.232,2232,069
Upgrade
Cash Growth
179.62%-1.00%-51.57%-64.63%7.46%-14.78%
Upgrade
Accounts Receivable
62.610.079.40.332.52-
Upgrade
Other Receivables
7.9131.5827.4327.3625.3125.57
Upgrade
Receivables
70.5231.6536.8327.6927.8425.57
Upgrade
Inventory
264.78217.84108.29170.8490.3350.08
Upgrade
Prepaid Expenses
82.6849.1878.3558.9560.85119.25
Upgrade
Total Current Assets
1,500675.62604.211,0442,4022,264
Upgrade
Property, Plant & Equipment
2,3431,8271,9282,1512,1141,906
Upgrade
Other Intangible Assets
3,5727.073.3812.0710.1711.96
Upgrade
Other Long-Term Assets
13.48225.3227.67213.47187.58190.98
Upgrade
Total Assets
7,6542,7352,7633,4204,7144,373
Upgrade
Accounts Payable
6.19-----
Upgrade
Accrued Expenses
-134.27-115.93137.49210.99
Upgrade
Current Portion of Long-Term Debt
-----54.77
Upgrade
Current Portion of Leases
184.36160.01163.45124.6588.7565.74
Upgrade
Current Income Taxes Payable
26.89-----
Upgrade
Current Unearned Revenue
37.7911.116.9128.07--
Upgrade
Other Current Liabilities
263.3342.75193.3834.6322.2821.6
Upgrade
Total Current Liabilities
518.56348.14363.73303.29248.51353.1
Upgrade
Long-Term Debt
-----35.53
Upgrade
Long-Term Leases
1,5821,4881,5681,7151,6701,363
Upgrade
Long-Term Unearned Revenue
4.155.4710.23---
Upgrade
Other Long-Term Liabilities
---10.47--
Upgrade
Total Liabilities
2,1051,8421,9422,0281,9191,752
Upgrade
Common Stock
2,3861,6411,3403,5273,5253,116
Upgrade
Additional Paid-In Capital
17,90613,56712,43111,06110,9889,653
Upgrade
Retained Earnings
-14,602-14,136-12,755-12,969-11,327-9,784
Upgrade
Comprehensive Income & Other
-140.71-177.94-194.17-227.09-390.12-364.04
Upgrade
Shareholders' Equity
5,549893.31821.111,3912,7952,621
Upgrade
Total Liabilities & Equity
7,6542,7352,7633,4204,7144,373
Upgrade
Total Debt
1,7661,6481,7321,8391,7591,519
Upgrade
Net Cash (Debt)
-689.29-1,271-1,351-1,053463.95549.19
Upgrade
Net Cash Growth
-----15.52%-73.66%
Upgrade
Net Cash Per Share
-3.88-8.19-10.48-8.954.276.14
Upgrade
Filing Date Shares Outstanding
238.61164.07133.96117.64117.57103.95
Upgrade
Total Common Shares Outstanding
238.61164.07133.96117.64117.57103.95
Upgrade
Working Capital
981.53327.48240.48740.432,1531,910
Upgrade
Book Value Per Share
23.265.446.1311.8323.7725.21
Upgrade
Tangible Book Value
1,977886.24817.731,3792,7852,609
Upgrade
Tangible Book Value Per Share
8.285.406.1011.7323.6825.10
Upgrade
Machinery
-1,089982.54975.18889.53884.87
Upgrade
Construction In Progress
-44.3483.7172.8253.848.78
Upgrade
Leasehold Improvements
-509.94415.69388.62318.95322.42
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.